Seeking Alpha

bestdamnpennys4...'s  Instablog

bestdamnpennys4bucks
Send Message
BestDamnPennys4Bucks.com is a multi-media marketing company that provides public awareness campaigns to increase liquidity for our client companies. In addition, we predict the Hottest picks available in the industry for our members to invest their hard earned money in. Our picks are... More
My company:
Bestdamnpennys4bucks.com
My blog:
BestDamnPennys4Bucks LLC
  • Titan Pharmaceutical Inc. 0 comments
    Mar 27, 2013 2:06 PM | about stocks: TTNP

    Titan Pharmaceuticals Inc

    Titan Pharmaceuticals Inc (OTCQB:TTNP), is a biopharmaceutical company specializing in the development of products for treatment of central nervous system diseases (NYSE:CNS). TTNP's chief asset is Probuphine, a slow-release implant medication of buprenorphine hydrochloride. Buprenorphine hydrochloride is a semi-synthetic opioid considered to be more than 25 times more effective than the coveted morphine pain reliever. The drug is designed to maintain a stable, 24/7 blood level of the formulation in patients for up to six months, ensuing a single treatment. First launched in 2011, is now available in a seven day transdermal patch for the of chronic pain patients. The transdermal patch is subdermally implanted in the patient's upper arms, providing continuous pain relief. This form of administration reduces the illegal use of the drug and helps prevent accidental overdose which can become prevalent with oral medication forms. In October 2012, the FDA received request for approval for the new drug to be administered also for opioid dependency, to combat opioid addictions.

    Titan Pharmaceuticals Inc, hopes to enter into several partnerships other pharmaceutical companies and commercialize Probuphine in U.S. and foreign markets.

    Secondly, Titan Pharmaceuticals Inc. currently is entitled to 8-10% of net sales for the drug Fanapt (iloperidone), which is an antipsychotic approved by the FDA (May 2009) for the treatment of schizophrenia and marketed by Novartis Pharma AG ("Novartis") in the U.S. This sublicense agreement with Novartis, is based on a patent which will not expire until October 2016.

    TTNP's stock price is currently $1.68. The price over the past 52 weeks has a range of $0.60 to $2.53, with a market cap of $126.36 million. The company is poised to make huge gains again soon. Previous close $1.73.

    To stay updated and informed on all changes with TTNP and many other companies, subscribe to bestdamnpennys4bucks.com and receive a free newsletter today.

    Chart for TTNP.OB

    TTNP

    Sunil Bhonsle

    Robert E. Farrell

    Brian Crowley

    http://www.titanpharm.com/

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

    Themes: TTNP Blog Stocks: TTNP
Back To bestdamnpennys4bucks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments


Most Commented
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.